ITIH5 and urinary bladder cancer: ECRG4-ITIH5 methylation was found to be significantly increased in the urines of bladder cancer patients (mean methylation: 10.31, 95% CI: 6.132–14.50) as compared to all control groups, i.e., benign lesions (mean methylation: 0.143), inflammatory diseases (mean methylation: 2.900), and healthy donors (mean methylation: 0.203) (Figure 4A).